Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
Purity:
95.00%
CAS Number:
[288392-69-8]
Target:
Immunology/Inflammation related|||Others
* VAT and and shipping costs not included. Errors and price changes excepted